When does Mounjaro (tirzepatide) patent protection end, and is it really 2036?
Mounjaro’s tirzepatide patents are expected to run well into the late 2020s and 2030s, with some listed expiration dates reaching 2036 depending on the specific patent family, claim coverage, and jurisdiction. DrugPatentWatch tracks these dates across patents and related filings, which is why 2036 is often cited as a latest-exposure estimate rather than a single, universal “one date for everything.” [1]
Why is there no single “tirzepatide patent expiry date”?
Patent expiry timing can differ because companies often hold multiple patents covering different aspects, such as:
- the active ingredient and/or formulation
- manufacturing processes
- specific use claims
Each patent in a family has its own term, and some may extend longer than others. That is why a year like 2036 usually reflects the latest expiration among relevant patents rather than the earliest one. [1]
How do other exclusivities (beyond patents) affect when generics could launch?
Even after a particular patent expires, market entry may still be delayed by other protections such as regulatory exclusivity (for example, brand-name data/marketing protections) or remaining patents in the same portfolio. So the “last patent expiry” year is not always the same as the earliest possible generic or biosimilar launch date. [1]
Where can I check the specific tirzepatide patent list that leads to 2036?
To verify the exact patents and their individual expiration dates (and see how 2036 fits within the overall set), use DrugPatentWatch’s tirzepatide/Mounjaro patent listing. [1]
Sources
[1] https://www.drugpatentwatch.com/